Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir

17 Apr 2025

Abstract excerpt

ABSTRACT Lenacapavir (LEN) is a first-in-class capsid (CA) inhibitor for the treatment and prevention of HIV-1 infection. While LEN has shown potent antiviral activity across all major HIV-1 subtypes, the impact of existing HIV-1 CA sequence diversity on the activity of LEN remains to be determined. Here, we identified natural polymorphisms within the LEN-binding site and assessed each for their impact on viral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40243329
DOI: 10.1128/mbio.00187-25

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavirPMID 40243329Read ↗

Lenacapavir treatment-emergent HIV-1 capsid resistance mutations are frequently associated with replication defects.Semantic proximity Read ↗

Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir.Semantic proximity Read ↗

Recurrent and novel evolutionary pathways drive in vitro HIV-1 lenacapavir resistance with diverse phenotypic consequences.Semantic proximity Read ↗

Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.Semantic proximity Read ↗

Structural and Mechanistic Bases for Resistance of the M66I Capsid Variant to LenacapavirSemantic proximity Read ↗

HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor LenacapavirSemantic proximity Read ↗

HIV-1 capsid variability: viral exploitation and evasion of capsid-binding moleculesSemantic proximity Read ↗

Rapid HIV-1 genotyping assay for the detection of capsid mutations.Semantic proximity Read ↗

Functional conservation of HIV-1 Gag: implications for rational drug design.Semantic proximity Read ↗

Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patientsSemantic proximity Read ↗

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 YearsSemantic proximity Read ↗

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.